Brief: Beyondspring Announces Positive Final Phase 3 DUBLIN-3 Data With The Plinabulin/Docetaxel Combination Vs Docetaxel Alone
20/09/2021 12:53
Sept 20 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING PHARMACEUTICALS ANNOUNCES POSITIVE FINAL
PHASE 3
DUBLIN-3 DATA WITH THE PLINABULIN/DOCETAXEL COMBINATION VERSUS
DOCETAXEL ALONE IN 2ND/3RD LINE NON-SMALL CELL LUNG CANCER
PATIENTS WITH EGFR WILD TYPE AT THE EUROPEAN SOCIETY FOR MEDICAL
ONCOLOGY (ESMO) 2021 CONGRESS
* BEYONDSPRING - STUDY MET PRIMARY ENDPOINT SHOWING
STATISTICALLY
SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR COMBINATION (DP)
VERSUS. DOCETAXEL
* BEYONDSPRING - STUDY MET KEY SECONDARY ENDPOINTS SHOWING
STATISTICALLY SIGNIFICANT IMPROVEMENT FOR DP VERSUS. D IN ORR,
PFS, AND 24- AND 36-MONTH OS RATES
* BEYONDSPRING - IN PD-1/PD-L1 EXPOSED PATIENTS, DP HAD
LONGER OS
BENEFIT VERSUS. D AND 24 M OS RATE IN COMBINATION WAS TRIPLE
THAT OF DOCETAXEL
* BEYONDSPRING INC - DP IS WELL TOLERATED, WITH LOWER GRADE
4 AND
GRADE 3/4 AE EVENTS PER PATIENT PER YEAR VERSUS. D
* BEYONDSPRING INC - NO UNEXPECTED AE CONCERNS WERE
IDENTIFIED
* BEYONDSPRING - PLANS TO SEEK U.S. FDA, CHINA NMPA APPROVAL
FOR
PLINABULIN WITH DOCETAXEL IN 2ND/3RD LINE NSCLC BASED ON SHOWED
CLINICAL BENEFIT, SAFETY PROFILE
Source text for Eikon: ID:nGNX4NBGHj
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value